Stratification of urinary bladder carcinoma based on immunohistochemical expression of CK5, CK14 and CK20

Al-Sharaky, Dalia Rifaat; Abdelwahed, Moshira; Asaad, Nancy Youssef; Foda, Amira; Abdou, Asmaa Gaber

doi:10.1080/15321819.2020.1845726

Cited by 5 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The DN subtype accounted for approximately 10% of cases in the study by Bejrananda et al and was associated with the worst 5-year overall survival (OS), with a hazard ratio as high as 3.29 [ 30 ]. Accordingly, CK5−/CK20− DN tumors were as many as 13% in the study by Al-Sharaky et al [ 36 ]. The prevalence rates of DN tumors raised to 25.7% and 60% in two cohorts of UTUCs and NMIBCs, respectively [ 33 , 75 ].…”

Section: Ihc-based Molecular Subtypesmentioning

confidence: 99%

“…Basal-like, or basal/squamous cell carcinoma-like (Bas), is usually regarded as the most aggressive subtype, showing unfavorable pathological features (namely, multifocality, higher stage, and the presence of nodal metastases), along with low survival rates [ 8 , 10 , 20 , 28 , 36 ], as well as the most represented in the consensus molecular classification [ 13 ]. Due to their longer lifespan as compared to umbrella cells, basal cells are expected to collect a higher number of genomic changes, including alterations in their chromatin landscape, such as mutations in histone- and chromatin-modifying genes [ 8 ].…”

Section: Ihc-based Molecular Subtypesmentioning

confidence: 99%

“…Conversely, the CK5/6+/GATA3+ DP subtype identified in the MIBC cohort assessed by Bejrananda et al showed a significantly higher OS of 42.8% as compared to other subgroups [ 30 ]. In the study by Al-Sharaky et al, DP tumors showed both favorable and unfavorable clinical features (namely, high grade along with lack of muscle invasion) [ 36 ].…”

Section: Ihc-based Molecular Subtypesmentioning

confidence: 99%

“…Interestingly, several recent studies [ 27 , 30 , 36 , 73 ] identified combined staining for both luminal and basal markers in a variable number of cases, ranging from 37.9% to 65.7% of their BCs (mostly MIBC). The CK5/6+/CK20+ DP subgroup identified by Kim et al showed the strongest immune signature gene expression at transcriptional analysis, and similar features as CK5/6+/CK20- Bas tumors at Gene Ontology, Ingenuity Pathway, and Gene Set Enrichment Analysis [ 42 ].…”

Section: Ihc-based Molecular Subtypesmentioning

confidence: 99%

See 3 more Smart Citations

Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation

Sanguedolce

Zanelli

Palicelli

et al. 2022

IJMS

View full text Add to dashboard Cite

Following several attempts to achieve a molecular stratification of bladder cancer (BC) over the last decade, a “consensus” classification has been recently developed to provide a common base for the molecular classification of bladder cancer (BC), encompassing a six-cluster scheme with distinct prognostic and predictive characteristics. In order to implement molecular subtyping (MS) as a risk stratification tool in routine practice, immunohistochemistry (IHC) has been explored as a readily accessible, relatively inexpensive, standardized surrogate method, achieving promising results in different clinical settings. The second part of this review deals with the pathological and clinical features of the molecular clusters, both in conventional and divergent urothelial carcinoma, with a focus on the role of IHC-based subtyping.

show abstract

Section: Ihc-based Molecular Subtypesmentioning

confidence: 99%

Section: Ihc-based Molecular Subtypesmentioning

confidence: 99%

Section: Ihc-based Molecular Subtypesmentioning

confidence: 99%

Section: Ihc-based Molecular Subtypesmentioning

confidence: 99%

See 2 more Smart Citations

Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation

Sanguedolce

Zanelli

Palicelli

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Dalia R Al-Sharaky et al, observed that most squamous cell carcinoma and those associated with bilharziasis were belonged to Ck5+/CK20-subgroup while pure UC and those lacked bilharziasis were located in the Ck5+/CK20+ subgroup [23]. IHC observations demonstrate that about 67% of bladder cancers with squamous differentiation express EGFR.…”

Section: Immunohistochemical (Ihc) Markers Of Scc Urinary Bladdermentioning

confidence: 99%

Squamous Cell Carcinoma of the Urinary Bladder: Clinicopathological and Molecular Update

Jagtap¹,

Jagtap²,

Kaur³

et al. 2021

ann urol oncol

View full text Add to dashboard Cite

Urinary bladder cancer is one of the most prevalent cancers worldwide.Squamous Cell Carcinoma (SCC) is an uncommon subtype of urinary bladder carcinoma.It is a malignant epithelial neoplasm arising in the urinary bladder demonstrating a pure squamous cell phenotype. On histopathology it is considered when tumor is showing pure squamous morphology without any component of conventional urothelial carcinoma. The SCC is a histologically distinct form of cancer. It arises from the uncontrolled multiplication of cells showing particular cytological or tissue architectural characteristics of squamous cell differentiation, such as the presence of keratin, tonofilament bundles or desmosomes. Majority of bladder SCC are high grade, high stage tumors with most cancers having muscle invasion at the time of diagnosis while overall about 80% of bladder cancers are non-muscle invasive bladder cancer at diagnosis.COX-2 is markedly expressed in all SCCs. An increased COX-2 level induces the development of SCC of the bladder affecting many biological features of this tissue including apoptosis, cell adhesion, angiogenesis and invasiveness.TERT promoter mutations, commonly found in conventional urothelial carcinoma, are also highly prevalent in urinary bladder squamous cell carcinoma suggesting a common tumorgenesis and potential utility as a molecular urine-based-screening assay.This review summarizes the current features related to clinical , pathological, and molecular features of SCC of urinary bladder.

show abstract

Trimodal Therapy for T3 Muscle-Invasive Bladder Cancer：a retrospective case series study

Chen,

Luo,

et al. 2024

Preprint

View full text Add to dashboard Cite

BACKGROUND: Bladder sparing therapy not only preserves bladder function and improves quality of life for patients, but also achieves survival rates similar to radical cystectomy. OBJECTIVE: To investigate the therapy of T3 muscle invasive bladder cancer (MIBC) by transurethral photo-selective vaporization of bladder tumors (PVBT) combined with radiotherapy and chemotherapy, and to accumulate evidence for further research. METHODS: This a retrospective case series study. The T3 bladder cancer patients received PVBT combined with preoperative neoadjuvant radiotherapy and postoperative adjuvant chemo-radiotherapy were selected from January 2018 to December 2020. The tumor changes after neoadjuvant radiotherapy, adverse reactions of chemo-radiotherapy, and the incidence of complications were followed up by outpatient and telephone. The expression of CK20, FGFR3, PLEKHG4B, CK6, and Desmin was detected by immunohistochemistry, and the factors affecting the recurrence and survival of bladder cancer were statistically analyzed. RESULTS: A total of 48 patients completed PVBT were included. The maximum diameter of the tumor was 0 ~ 6.0 cm after neoadjuvant radiotherapy, with an average of 2.1 cm, which was smaller than that pre-radiotherapy (P< 0.05). The number of tumors decreased by 11 cases (47.83%), the clinical stage of tumors decreased by 13 cases (27.08%) and 42 cases (87.50%) had varying degrees of radiation or chemotherapy toxicity. During the follow-up period, 22 patients (45.83%) experienced recurrence, and 10 patients died of distant organ metastasis or cachexia. Multivariate Cox regression analysis showed that tumor diversity and FGFR3 gene affect the recurrence of bladder tumor, while age and tumor diameter affect the survival rate of bladder tumors. CONCLUSIONS: This study is the small-scale case series study ofT3 bladder cancer patients received PVBT combined with preoperative neoadjuvant radiotherapy and postoperative adjuvant chemo-radiotherapy, which is an effective method to treat T3 MIBC. Meanwhile, monitoring FGFR3 in patients with MIBC is very important for evaluating prognosis.

show abstract

Stratification of urinary bladder carcinoma based on immunohistochemical expression of CK5, CK14 and CK20

Cited by 5 publications

References 28 publications

Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation

Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation

Squamous Cell Carcinoma of the Urinary Bladder: Clinicopathological and Molecular Update

Trimodal Therapy for T3 Muscle-Invasive Bladder Cancer：a retrospective case series study

Contact Info

Product

Resources

About